Jeffrey Joseph, MD
Ophthalmic Plastic and Reconstructive Surgery · Newport Beach, CANPI 1134395205
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $190,725 of the $292,265 with a category attached, or 65.3%. AbbVie accounts for 92.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $125,791 and has fallen 94.0% since, to $7,600 in 2025. Among ophthalmic plastic and reconstructive surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $1032.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$271K
- Galderma Laboratories, L.p.$21K
- Shire North American Group Inc$144
- Tarsus Pharmaceuticals, Inc.$143
- Helsinn Therapeutics (U.S.), Inc.$14
- VYNE Pharmaceuticals Inc.$13
What the payments were for
- Consulting fees$64,76522%
- Speaking & faculty fees$190,72565%
- Travel & lodging$27,87910%
- Food & beverage$8,8613%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 254 | $271,412 |
| Galderma Laboratories, L.p. | 22 | $20,539 |
| Shire North American Group Inc | 3 | $144 |
| Tarsus Pharmaceuticals, Inc. | 2 | $143 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| VYNE Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$129,425
- BOTOX COSMETIC$262
- XIIDRA$122
- XDEMVY$120
How this compares
$292,265 in reported general payments places this provider in the 95th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 94 | $789 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $117 |
| Lorazepam | 29 | $17 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $16 |
| Tramadol Hcl | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Newport Beach
- Marjan FaridIrvine$742K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
- Omar OzgurMission Viejo$16K
- Asa MortonSan Diego$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.